Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Intra-arterial Chemotherapy for the Treatment of Intraocular Retinoblastoma

This study has been terminated.
(IAC was initially not an available retinoblastoma treatment at Johns Hopkins. It is now recognized as part of the standard of care treatment options in the US.)
Sponsor:
Information provided by (Responsible Party):
Sidney Kimmel Comprehensive Cancer Center
ClinicalTrials.gov Identifier:
NCT01293539
First received: January 21, 2011
Last updated: August 24, 2016
Last verified: August 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: August 2021
  Estimated Primary Completion Date: August 2017 (Final data collection date for primary outcome measure)